What Pulse Medical does

Pulse Medical (Guangdong Pulse Medical Technology Co., Ltd. / 广东脉搏医疗科技有限公司) is a Chinese cardiovascular interventional medical device company headquartered in Zhuhai's National High-tech Industrial Development Zone, founded in 2014. The company develops, manufactures, and commercializes Class III implantable cardiovascular devices via a "medical-engineering integration" (医工结合) R&D model that integrates academicians, clinical experts from top Chinese tertiary hospitals, and its engineering teams. Its single commercial product is the Leftear® Left Atrial Appendage Occluder System — a disc-type (dual-body) occluder with a patented 10F delivery system — which received NMPA Class III Medical Device Registration (registration number 国械注准20223131295) in September 2022 after approximately eight years of development. The system targets stroke prevention in non-valvular atrial fibrillation patients, particularly those contraindicated to long-term oral anticoagulation, and is validated by a 196-patient multicenter trial demonstrating 100% immediate implantation success, 98.7% occlusion success at follow-up, and 0% device thrombus formation.

Beyond the Leftear system, Pulse Medical operates a broad in-development pipeline across four categories: cardiovascular implantable products (biodegradable PFO occluder, transcatheter biological mitral and tricuspid valves, left ventricular isolation/volume reduction system), cardiovascular interventional products (percutaneous vascular suture device, PFO suture device), sheath products (adjustable bending/delivery sheaths), and intelligent monitoring (wearable ECG garment). The company manufactures in-house at a GMP-certified facility in Zhuhai with a Class 10,000 cleanroom, sterile testing, and physical/chemical laboratories, and sells through direct enterprise sales to tertiary hospital cardiology departments, supplemented by a flagship distribution agreement with Johnson & Johnson Medical Technology (signed April 2024) and a Macau/Greater Bay Area partnership with Macau Nanguang Medical (signed October 2024). Revenue is generated through one-time hardware sales of high-value Class III implantable medical devices procured via hospital-level institutional purchasing, with pricing opaque and negotiated at the hospital level.

The company is venture-backed across four funding rounds (angel 2014; Series A 30M RMB in June 2019 led by ChenDe Capital; Series B ~100M RMB in December 2020 led by Shanlan Capital; Series C in August 2022 co-led by Weilai Capital and Guangdong Financial Biomedicine Fund). It has been recognized as a Guangdong Province "Specialized, Refined, Novel" SME (2022), a Zhuhai "unicorn seed enterprise" (May 2022), and listed on KPMG's inaugural China Healthcare Tech 50 (July 2025). Founder Ruan Chengmin serves as Chairman and CEO, with Prof. Xu Yawei (Director of Heart Center, Tongji University Affiliated Shanghai Tenth People's Hospital) as Chief Medical Officer.

Name

Pulse Medical

Legal name

广东脉搏医疗科技有限公司

Website

https://pulsemed.cn

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

11–50 employees

Short description

Pulse Medical (Guangdong Pulse Medical Technology Co., Ltd.) is a Zhuhai-based Chinese medical device company developing and commercializing Class III implantable cardiovascular devices, with its NMPA-approved Leftear® Left Atrial Appendage Occluder System serving tertiary hospital cardiology departments across China.

Ownership category

akta.pro rank

Product category

Cardiovascular Implantable Medical Devices

NAICS

Surgical Appliance and Supplies Manufacturing (339113), Surgical and Medical Instrument Manufacturing (339112), Electromedical and Electrotherapeutic Apparatus Manufacturing (334510)

SIC

Surgical & Medical Instruments & Apparatus (3841), Electromedical & Electrotherapeutic Apparatus (3845)

akta.pro primary industry

Thrombectomy, Embolic Protection & Stroke Intervention Devices (HLAHAFAJ)

akta.pro secondary industries

Cardiac Surgery Devices (Cannulas, Clamps, Closure, Grafts) (HLAHAFAH), Vascular Access & Closure Devices (Sheaths, Guidewires, Closure Systems) (HLAHAFAK), Cardiometabolic RPM & Chronic Disease Management (diabetes, hypertension, CHF, obesity) (HLALAFAA)

Keywords

• Left atrial appendage occluder
• Cardiovascular interventional devices
• Structural heart disease devices
• Cardiac implant manufacturing
• Stroke prevention devices

Headquarters

HQ city

Zhuhai

HQ country

China

HQ region

Asia

Offices1 record

Markets served

GTM type

B2B

Offering type

Hardware or Manufacturing

Cost components

Technology or R&D, Personnel, Operations, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

1. Cardiovascular Medical Device Sales: Pulse Medical generates revenue through the sale of approved cardiovascular implantable and interventional medical devices, primarily the Leftear left atrial appendage occluder system (registered with NMPA as Class III medical device, registration number 国械注准20223131295). The company manufactures its products in-house at its GMP-certified production facilities in Zhuhai and sells directly to hospitals and clinical institutions. Revenue is one-time device sale-based rather than recurring, typical of high-value Class III implantable medical device commercial models.

Go-to-market motion1 record

Distribution channels3 records

Marketing channels5 records

Core offering

Pulse Medical designs, develops, manufactures, and sells Class III implantable cardiovascular interventional medical devices in its GMP-certified production facilities in Zhuhai, China. Its flagship commercial product is the Leftear Left Atrial Appendage Occluder System (NMPA Class III registered September 27, 2022) used for stroke prevention in non-valvular atrial fibrillation patients. The company sells directly to tertiary hospitals and clinical institutions through hospital procurement, supplemented by strategic distribution partnerships with Johnson & Johnson Medical Technology and Macau Nanguang Medical.

Product overview

Pulse Medical is a specialized cardiovascular medical device company focused on structural heart disease products. The core commercial product is the Leftear® Left Atrial Appendage Occluder System, which received NMPA approval in September 2022. The product portfolio follows a platform-based architecture with the occlusion device at the center, supported by a proprietary delivery system. Beyond the commercialized product, the company maintains an extensive R&D pipeline spanning four categories: cardiovascular implantable products (including additional occluder variants and transcatheter valves), cardiovascular interventional products (vascular closure and suture devices), sheath products (delivery systems), and intelligent monitoring devices (wearable ECG monitoring). The company operates a "medical-engineering integration" R&D model, collaborating with clinical experts to drive product development.

Differentiator

Problem solved

Functional benefit

Brands

• Leftear: 左心耳封堵器系统 - 公司核心产品，包括左心耳封堵器与输送系统两大组成部分

Products and services

• Leftear Left Atrial Appendage Occluder System A dual-disc (disk) type left atrial appendage occlusion system designed for stroke prevention in non-valvular atrial fibrillation patients. The system consists of the left atrial appendage occluder and a 10F delivery system (delivery sheath, expander, delivery steel cable, and loader). Features improved fixation and sealing performance with shortened endothelialization time compared to existing U.S. and German competitor devices; achieved 100% immediate implantation success and 98.7% occlusion success rate in a 200-patient multicenter clinical trial. Sold to tertiary hospitals and cardiology centers in China.

Quantifiable outcome

• 100% immediate implantation success rate in 196/196 patients in multicenter clinical trial (200 enrolled, 196 implanted)
• +4 more outcomes

Named customers12 records

Segments3 records

Ideal customer profiles1 record

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature6 records

Partnerships

Five partnerships are on record, tiered core, flagship and minor.

• Macau Nanguang Medical Management Consulting Co., Ltd. (澳门南光医疗管理顾问有限公司)coreChannel Partner/ Reseller/ Distributor · 10 October 2024Product strategic cooperation agreement signed October 10, 2024 for the left atrial appendage occlusion system. The partnership covers product market promotion, brand building, and customer service in the Macau and Greater Bay Area markets. Represents a key regional distribution milestone for Pulse Medical in the Greater Bay Area.
• Johnson & Johnson Medical Technology (强生医疗科技)flagshipGTM or Marketing Partner · 18 April 2024Strategic product cooperation agreement signed on April 18, 2024 for the Leftear left atrial appendage occlusion system. Both parties committed to deepening long-term cooperation in left atrial appendage occlusion technology to provide diversified and more effective treatment solutions for atrial fibrillation patients across China. Johnson & Johnson Medical Technology leverages its extensive hospital network and commercial infrastructure for market expansion of Pulse Medical's products.
• 广东医谷 (Guangdong Medical Valley)minorStrategic or Co-development Partner · 21 April 2021Pulse Medical signed an agreement to relocate to the Guangdong Medical Valley (Zhuhai) Medical Industry Acceleration Base in April 2021, gaining access to shared infrastructure, industry cluster resources, and business support services within the medical industry park.
• Hong Kong Asian Heart Centre (香港亚洲心脏病中心)minorStrategic or Co-development Partner · 3 January 2020Signed cooperation agreement at the 2020 China (Guangdong) Cardiovascular Industry Innovation Transformation Summit Forum for collaboration in cardiovascular medical device innovation and clinical application.
• ICICO (China-Israel Cardiovascular Innovation Cooperation Organization)minorStrategic or Co-development Partner · 4 December 2016Pulse Medical participated in the founding of ICICO at the Israel Cardiovascular Expert Symposium in December 2016, Tel Aviv. ICICO was established to promote China-Israel cardiovascular innovation cooperation, bringing together experts from both countries. Pulse Medical's Leftear occluder received high praise from international experts at this event.

Scale indicators5 records

Recent moves8 records

Expansion highlights6 records

Direct peers

• Boston Scientific: Global market leader in left atrial appendage closure with the WATCHMAN/WATCHMAN FLX franchise — the dominant competitor to Pulse Medical's Leftear in both Chinese and international markets.
• Abbott: Manufacturer of the Amplatzer Amulet LAA occluder and a broad structural heart portfolio. Competes directly with Pulse Medical in transcatheter LAA closure and across the wider structural heart space.
• Peijia Medical: Hong Kong-listed Chinese structural heart company (9989.HK) developing its own LAA occluder and TAVR products — the closest direct Chinese competitor to Pulse Medical in import-substitution.
• Lifetech Scientific (Sinomed): Chinese cardiovascular implantable device maker with LAA occluder (LAmbre) and structural heart products — directly competes with Pulse Medical in Chinese hospitals pursuing the same import-substitution opportunity.
• Venus MedTech: Hong Kong-listed Chinese structural heart company (2500.HK) focused on transcatheter valve replacement — directly comparable in pipeline ambition (mitral/tricuspid valves overlap with Pulse Medical's R&D).
• MicroPort CardioFlow: MicroPort's cardiovascular subsidiary developing TAVR and structural heart devices. Comparable Chinese structural heart peer competing for the same KOL relationships and hospital procurement slots.

Emerging players

• Conformal Medical: U.S. early-stage company developing a next-generation LAA occluder (CLAAS system) — emerging peer in the same LAA closure category as Pulse Medical's Leftear.

Broad incumbents

• Edwards Lifesciences: Global structural heart leader (PASCAL, SAPIEN TAVR) and a benchmark competitor for Pulse Medical's transcatheter mitral/tricuspid valve pipeline programs.
• Medtronic: Diversified medical device incumbent with structural heart, LAA-related, and vascular closure products. Represents the broader competitive set Pulse Medical's pipeline will encounter at scale.

Others

• AtriCure: U.S. company specializing in atrial fibrillation surgical ablation and left atrial appendage management (AtriClip) — adjacent peer relevant to Pulse Medical's 'one-stop' combined ablation + LAAC clinical workflow.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

Compliance2 records

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds3 records

Investors2 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Pulse Medical